Published time: 11 April 2020
Authors: Brandon Michael Henry, Giuseppe Lippi
Keywords: Extracorporeal life support, Acute respiratory distress syndrome, Coronavirus, COVID-19
The novel coronavirus disease 2019 (COVID-19) can induce acute respiratory distress syndrome (ARDS), which can progress to refractory pulmonary failure. In such cases, extracorporeal membrane oxygenation (ECMO) may be considered as a rescue therapy. In a study of ECMO for ARDS in patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a similar coronavirus disease emerged in 2012, a significant decrease of in-hospital mortality rate and length of intensive care unit (ICU) stay was found in patients treated with ECMO compared to those managed with conventional therapy . However, with COVID-19, concerns have been raised about high mortality rate observed in an early report which included data on ECMO in infected patients . It has been suggested that the compounded immunologic insult by both infection and extracorporeal circuit may counterbalance or even offset survival benefits . In this article, we aimed to evaluate ECMO mortality as reported in early COVID-19 epidemiological studies.
Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19); Pooled analysis of early reports